期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 2, 页码 251-258出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604877
关键词
colorectal cancer; cetuximab; oxaliplatin; fluoropyrimidine; metastatic; first line
类别
资金
- Medical Research Council [MC_U122861325] Funding Source: Medline
- MRC [MC_U122861325] Funding Source: UKRI
- Medical Research Council [MC_U122861325] Funding Source: researchfish
We present the preliminary toxicity data from the MRC COIN trial, a phase III randomised controlled trial of first-line therapy in advanced colorectal cancer, with particular reference to the addition of cetuximab to an oxaliplatin-fluoropyrimidine combination. A total of 804 patients were randomised between March 2005 and July 2006 from 78 centres throughout the United Kingdom. Patients were allocated to oxaliplatin plus fluoropyrimidine chemotherapy with or without the addition of weekly cetuximab. The choice of fluoropyrimidine (either 5-fluorouracil (5FU) or capecitabine) was decided by the treating physician and patient before randomisation. Toxicity data were collected from all patients. Two hundred and three patients received 5FU plus oxaliplatin (OxMdG, 25%), 333 oxaliplatin + capecitabine (Xelox, 41%), 102 received OxMdG + cetuximab (OxMdG + C, 13%) and 166 Xelox + cetuximab (21%). Percent grade 3/4 toxicities included diarrhoea 6, 15, 13 and 25%, nausea/vomiting 3, 7, 7 and 14% for OxMdG, Xelox, OxMdG + C and Xelox + C, respectively. Sixty-day all-cause mortality was 6, 5, 5 and 7%. Statistically significant differences were evident for patients receiving Xelox + cetuximab vs Xelox alone: diarrhoea relative risk (RR) 1.69 (1.17, 2.43, P = 0.005) and nausea/vomiting RR 2.01 (1.16, 3.47, P = 0.012). The excess toxicity observed in the oxaliplatin-, capecitabine-, cetuximab-treated patients led the trial management group to conclude that a capecitabine dose adjustment was required to maintain safety levels when using this regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据